European Commission

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
четверг, мая 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, News, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Usenet newsgroup, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
четверг, мая 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, News, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Usenet newsgroup, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
четверг, мая 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, News, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
четверг, мая 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, News, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Royalty Pharma Reports First Quarter 2024 Results

Retrieved on: 
четверг, мая 9, 2024
FDA, Ulcerative colitis, KarXT, Food, MorphoSys, European Commission, Marketing, New Drug Application, Cystic fibrosis, PDSS, PANSS, Tourette syndrome, Lupus, Docetaxel, Roche, Schizophrenia, Novartis, ADP, Pfizer, Incidence, Bristol Myers Squibb, Patient, Neurology, Acquisition, Sacituzumab govitecan, Olanzapine, Civil service commission, Multiple sclerosis, Positive, Vertex, Sanofi, Teva Pharmaceuticals, Astellas Pharma, European Medicines Agency, Lung cancer, Pharmaceutical industry

During 2024, Royalty Pharma announced new transactions of up to $619 million.

Key Points: 
  • During 2024, Royalty Pharma announced new transactions of up to $619 million.
  • In January 2024, Royalty Pharma acquired a royalty interest in ecopipam for an upfront payment of $49 million and up to $44 million in milestone payments contingent on the achievement of certain regulatory milestones.
  • In May 2024, Royalty Pharma announced a transaction to acquire royalties and milestones on frexalimab owned by ImmuNext for approximately $525 million in cash including estimated transaction costs.
  • Royalty Pharma has provided guidance for full year 2024, excluding transactions and borrowings announced after the date of this release, as follows:

UFCW Canada hosts North America’s first Social Partner Forum on Decent Work in the Agrifood Sector

Retrieved on: 
среда, мая 8, 2024
Congress, Organization, UFCW, Restaurant, RWDSU, Food industry, Social Development Canada, Collective bargaining, European Commission, IUF, Collective Bargaining Convention, 1981, ILO, Loblaws, Agriculture, Employment, Maple Leaf Foods, Civil service commission, International Labour Organization, Tobacco, Government, International Brotherhood of Teamsters, Metro, Haggerty

The promotion of decent work for all is a key objective of the UN’s 2030 sustainable development goals .

Key Points: 
  • The promotion of decent work for all is a key objective of the UN’s 2030 sustainable development goals .
  • While Europe has held social partner discussions on decent work for many years, this forum was the first of its kind for Canadian stakeholders.
  • Together, we are best positioned to advance decent work throughout the food system and supply chain.”
    This forum brought together social partners from unions, employers, and governments.
  • And government was represented by Agriculture and Agrifood Canada, Employment and Social Development Canada, and the Ontario Ministry of Labour, Immigration, Training and Skills Development.

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of iRobot

Retrieved on: 
вторник, мая 7, 2024
LLP, FTC, RVC, POLITICO, News, Reuters, Advertising, European Commission, Amazon, Court, IRobot, European Economic Area, Acquisition, Civil service commission, Bloomberg, Workforce, IRBT

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding iRobot’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

Travere Therapeutics Reports First Quarter 2024 Financial Results

Retrieved on: 
понедельник, мая 6, 2024
FDA, Total, Risk, Ligand Pharmaceuticals, European Commission, Research, UPCR, Webcast, HCU, IND, EGFR, PDUFA, SIMD, Civil service commission, Diagnosis, PMDA, GAAP, CMA, Congress, Table, PROTECT, Priority review, Food, Abstract, FSGS, Income tax, CSL Vifor, Quarter, Medication, Therapy, SAN, Plasma, Urine, International, Safety, Proteinuria, ANNA, Immunoglobulin A, Homocysteine, Investigational New Drug, Society, Shanda, New Drug Application, Genetic, European, Disease, Patient, Quality of life (healthcare), IPR, Bank statement, Growth, Pharmaceutical industry

Net product sales for the first quarter of 2024 were $40.0 million, compared to $24.2 million for the same period in 2023.

Key Points: 
  • Net product sales for the first quarter of 2024 were $40.0 million, compared to $24.2 million for the same period in 2023.
  • Travere Therapeutics will host a conference call and webcast today, Monday, May 6, 2024, at 4:30 p.m.
  • ET to discuss company updates as well as first quarter 2024 financial results.
  • The Company believes that these non-GAAP financial measures are helpful in understanding its past financial performance and potential future results.

BeiGene Reports First Quarter 2024 Financial Results and Business Updates

Retrieved on: 
среда, мая 8, 2024
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, FDA, Obinutuzumab, Acalabrutinib, NMPA, Food, Sustainability, European Commission, Progression-free survival, Fulvestrant, MTA, ASCEND, ESCC, Patent, PDUFA, ADC, CLL, Patient, CDK4, Symantec Endpoint Protection, Chronic lymphocytic leukemia, HPK1, Tislelizumab, BLA, Anticipation, EGFR, NSCLC, CDK2, GAAP, Food and Drug Administration, Growth, Lung cancer, Pharmaceutical industry

Product Revenue for the three months ended March 31, 2024, was $747 million, compared to $410 million in the same period of 2023, representing an increase of 82%.

Key Points: 
  • Product Revenue for the three months ended March 31, 2024, was $747 million, compared to $410 million in the same period of 2023, representing an increase of 82%.
  • The increase in product revenue was attributable to increased sales of our internally developed products, BRUKINSA and tislelizumab.
  • Gross Margin as a percentage of global product revenue for the first quarter of 2024 was 83%, compared to 80% in the prior-year period.
  • The gross margin percentage increased primarily due to proportionally higher sales mix of global BRUKINSA compared to other products in the portfolio.

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

Retrieved on: 
среда, мая 8, 2024
Biotechnology, Infectious Diseases, COVID-19, Health, Pharmaceutical, Society, COVID, Investment, Meiji, ARCT, Ornithine transcarbamylase deficiency, Safety, SARS-CoV-2, Travel, European Commission, Research, OTC, Cystic fibrosis, Lyme disease, RNA, MAA, Inborn errors of metabolism, Trial of the century, Vaccine, CDMO, Omicron, SRR, GMT, SAD, Liver, CSL, EMA, JPMorgan Chase, SIMD, Civil service commission, Infection, Messenger, Arcturus Therapeutics, Therapy, European Medicines Agency, Pharmaceutical industry

“Arcturus continues to make encouraging progress in both our vaccine and therapeutics pipeline,” said Joseph Payne, President & CEO of Arcturus.

Key Points: 
  • “Arcturus continues to make encouraging progress in both our vaccine and therapeutics pipeline,” said Joseph Payne, President & CEO of Arcturus.
  • To support this effort, Arcturus along with CDMO partners are on track to deliver the initial 4 million commercial doses of Kostaive in Q3.
  • The Company will share a progress update on the Phase 2 study on July 1, 2024.
  • The expected cash runway extends at least three years based on the current pipeline and programs through the first quarter of fiscal year 2027.